English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols

Kanaan, A. S., Jakubovski, E., & Müller-Vahl, K. (2017). Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sciences, 7(5): 47. doi:10.3390/brainsci7050047.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0002-E198-4 Version Permalink: http://hdl.handle.net/21.11116/0000-0004-4D9E-5
Genre: Journal Article

Files

show Files
hide Files
:
Kanaan_Jakubovski_2017.pdf (Publisher version), 362KB
Name:
Kanaan_Jakubovski_2017.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Kanaan, Ahmad S.1, 2, Author              
Jakubovski, Ewgeni 2, Author
Müller-Vahl, Kirsten 2, Author
Affiliations:
1Methods and Development Unit Nuclear Magnetic Resonance, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634558              
2External Organizations, ou_persistent22              

Content

show
hide
Free keywords: Tourette syndrome; tic disorders; nabiximols; endocannabinoid system
 Abstract: Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff/day (= 100 μL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 × 3 puffs/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting

Details

show
hide
Language(s): eng - English
 Dates: 2017-04-052017-03-072017-04-192017-04-26
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.3390/brainsci7050047
PMID: 28445405
PMC: PMC5447929
PII: E47
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Brain Sciences
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Basel, Switzerland : Multidisciplinary Digital Publishing Institute (MDPI)
Pages: - Volume / Issue: 7 (5) Sequence Number: 47 Start / End Page: - Identifier: ISSN: 2076-3425
CoNE: https://pure.mpg.de/cone/journals/resource/2076-3425